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Glycemic Control and
Complications in Type II
Diabetes
I
n our opinion. the objectives of both
he feasibility tnal and the study that is
intended to ensue from it. as pre-
sented by Dr. Abraira et al. (VA CS
Group) ( I). are highly relevant. If it is
possible to achieve and maintain a statis-
tically significant difference in HbA 1  be-
tween two otherwise comparable
groups—within the acceptable range of
glycemic values. that is—we can finally
address the ultimate question of what
target level of glycemic control can best
he strived for in type II diabetes.
In I989. our research group the
Hoom Study) planned a very similar fea-
sibility study. which is currently in the
recniitment phase. lust as the VA CS
Group. we also had concerns about the
difference in intensity of care between
the two treatment arms. possibly leading
to a different degree of unintended effects
in both arms during follow-up. which
cannot always he measured precisely nor
attributed to the level of glycemic con-
trol. If. during follow-up. a difference in
both HbA„ and. e.g.. lipid levels or blood
pressure should develop. we would not be
able to ascertain whether the changes in
these other risk factors would be attribut-
able to glycemic level alone or partly to
unintended differences in, e.g., dietary
habits or physical fitness. So, if the main
aim is to investigate the effect of glycemic
control per se on macrovascular end
points. it is necessary to make sure that any
difference between the two groups after
follow-up is attributable to the difference
in level of glycemic control alone. As it is
not feasible to mask determinant categories
for both diabetes care professionals and
patients. we are convinced that this prob-
lem cannot be fully overcome.
The second problem to be ad-
dressed arises from the comparison of a
well-defined intensive treatment strategy
with a less-defined standard treatment
that could change over time (not only in
the course of the feasibility study. but
also during an ensuing long-term trial). If
a significant difference is established at
one year, this does not guarantee main-
tenance of the difference over a longer
period of time. For this to occur. a firm
grip on both treatment arms is required.
On one hand. it is pivotal to prevent
so-called contamination. as it reduces
the differences between the level of gly-
cemic control in the groups: one may
expect that the results of the standard
treatment gradually come closer to those
of the intensive treatment. On the other
hand, it cannot be excluded that glyce-
mic control during standard treatment
would not be good enough to reach even
acceptable levels. In this latter case. the
real question—which level of glycemic
control is necessary to prevent complica-
tions—cannot be answered. Both scenar-
ios illustrate the necessity of having strict
control over both arms of the study.
As a consequence of our view
concerning these two potential prob-
lems. we have chosen a study design that
differs from that of the VA CS Group on
the following points: All participating
type Il diabetic patients are treated by
their own general practitioner according
to the same standardized step-up regi-
men, in collaboration with a diabetes ed-
ucator and our research center. where
facilities for education and consultation
are provided. After baseline measure-
ments, patients are randomly assigned to
two (equally intensive) treatment groups:
the only contrast between these groups
being the target values of glycemic con-
trol. which are a fasting capillary blood
glucose level 5_6 mM or a fasting glucose
58 mNI (rounded numbers) for the in-
tensive and standard groups. respec-
tively. Participating general practitioners
are asked to implement the next treat-
ment step if the target has not been
reached yet. and to refrain from taking
any steps as soon as the assigned target
values are reached. In theory. this design
creates two equally well-defined, inten-
sively treated groups. with the only dif-
ference being the glycemic values, both
within the acceptable range.
In conclusion, we think it is es-
sential in studies like these to ensure that
the degree of attention and education
provided to the patients in the compared
groups is fully similar, in order to pro-
vide a clear answer to an extremely im-
portant question.
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Response to Van der
Does et al.
e appreciate the interest and
comments of Dr. Van der Does
et al. We, too, are concerned
that the two randomized groups must be
the same in all respects except for the
level of glycemic control. Our trial has
been carefully designed to prevent unin-
tended effects of risk factors between
arms by defining identical patient educa-
tion and treatments for these risk factors
in both treatment groups. Should unex-
pected differences appear, these risk fac-
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tors will be included as covanates in the
statistical analysis of results. In the long-
term tnal. we will further attempt to pre-
vent imbalances by having both groups
of patients seen in the clinic every 6 wk.
The second problem mentioned
by Dr. Van der Does is already partially
answered in the preliminary report of the
results of the feasibility trial. which
shows that the control group retains the
prevalent fasting glycemic level of the full
cohort at entry. 12 mM, which is similar
to outpatient assessments both here and
in Europe (1.2). By contrast. the mean
fasting glycemia in the intensive group is
6 mM. whereas the level of separation
between groups remains consistent for
>2 yE of follow-up (1). These levels are
similar to those reported for several years
in the DCCT (3). We believe it is highly
unlikely that the HbA„ values in the stan-
dard group will drift significantly toward
the intensively treated group. Our tnal is
monitored by an independent data moni-
tonng board. Should a satisfactory HbA,,
separation not be maintained between the
two treatment groups. mechanisms ex-ist in
the CS program to stop the trial.
It would appear that by design.
the Hoom Study aims at a narrow level
of ;ziycemic separation. not unlike those
obtained in the different intervention
arms in the L'I∎T'IDS (4). These European
studies in type II diabetes. and the \'A
CSDNI, will likely complement each
other. If glycemic regulation is effective
in preventing macrovascular events. it
will he important to determine the de-
sired level of HbA,. By choosing two
intensive levels of glycemic regulation,
the Hoom Study may help determine
this level. On the other hand, if glycemic
regulation is important. the macrovascu-
lar event rates in these two intensive
arms may be similar. In this case. a very
large sample size may be required for
meaningful results to emerge.
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